Jade Biosciences, Inc. (JBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jade Biosciences, Inc. (JBIO) has a cash flow conversion efficiency ratio of -0.081x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.08 Million) by net assets ($296.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Jade Biosciences, Inc. to measure how many days the company can operate on defensive assets alone.
Jade Biosciences, Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Jade Biosciences, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Jade Biosciences, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jade Biosciences, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cardinal Infrastructure Group Inc. Class A Common Stock
NASDAQ:CDNL
|
0.000x |
|
Garcia Reguera S.A.
BA:REGE
|
-0.126x |
|
Huafa Industrial Co Ltd Zhuhai
SHG:600325
|
0.074x |
|
Gallant Micro Machining Co Ltd
TWO:6640
|
0.080x |
|
China Hi-Tech Group Co Ltd
SHG:600730
|
-0.007x |
|
Bonheur
OL:BONHR
|
0.082x |
|
Altamir SCA
PA:LTA
|
0.028x |
|
CW Enerji SA
IS:CWENE
|
0.013x |
Annual Cash Flow Conversion Efficiency for Jade Biosciences, Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Jade Biosciences, Inc. from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see JBIO market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $332.52 Million | $-94.69 Million | -0.285x | +69.43% |
| 2024-12-31 | $76.43 Million | $-71.20 Million | -0.931x | -79.57% |
| 2023-12-31 | $109.46 Million | $-56.78 Million | -0.519x | -68.05% |
| 2022-12-31 | $126.74 Million | $-39.12 Million | -0.309x | -94.24% |
| 2021-12-31 | $172.42 Million | $-27.40 Million | -0.159x | +94.05% |
| 2020-12-31 | $2.94 Million | $-7.86 Million | -2.672x | -- |
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Ja… Read more